Related Experiment Video
Updated: Jan 25, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Immunosuppressive therapy with rituximab in common variable immunodeficiency.
Antonio Pecoraro1, Ludovica Crescenzi1, Maria Rosaria Galdiero1
11Department of Translational Medical Sciences and Center for Basic and Clinical Immunology Research (CISI), World Allergy Organization (WAO) Center of Excellence, University of Naples Federico II, Via S. Pansini 5, 80131 Naples, Italy.
Rituximab effectively treats autoimmune and lymphoproliferative issues in Common Variable Immunodeficiency (CVID). Further research is needed to confirm long-term safety and efficacy for these non-infectious CVID complications.
Area of Science:
- Immunology
- Hematology
- Rheumatology
Background:
- Common Variable Immunodeficiency (CVID) is a primary antibody deficiency causing low IgG and IgA.
- Non-infectious complications like autoimmunity and lymphoproliferation are major causes of morbidity and mortality in CVID.
- Management of CVID complications is challenging, often requiring immunosuppressive therapies.
Purpose of the Study:
- To review the evidence on rituximab's use in treating CVID complications.
- To discuss B-cell depletion mechanisms of rituximab.
- To analyze rituximab's efficacy in autoimmune cytopenias, GLILD, and lymphoproliferative syndromes.
Main Methods:
- Literature review of studies on rituximab for CVID complications.
- Analysis of proposed mechanisms for rituximab-mediated B-cell depletion.
- Focus on autoimmune cytopenias, granulomatous lymphocytic interstitial lung disease (GLILD), and non-malignant lymphoproliferative syndromes.
Main Results:
- Rituximab has shown effectiveness and relative safety in treating CVID-related autoimmune and lymphoproliferative conditions.
- Studies indicate rituximab is a viable therapeutic option for these complications.
- Data on long-term efficacy and side effects are currently lacking.
Conclusions:
- Rituximab appears to be an effective and safe treatment for specific non-infectious complications of CVID.
- More randomized controlled trials are necessary to establish long-term outcomes and optimize treatment strategies.
- Further research is crucial for managing CVID's non-infectious complications effectively.
Related Concept Videos
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Common Ion Effect
Variability: Analysis
The range is a simple measure of variability, indicating the difference between the highest and...
Random Variables
Uppercase letters such as X or Y denote a random variable. Lowercase letters like x or y denote the value of a random variable. If X is a random variable, then X is written in words, and x is given as a number.
For example, let X = the...
Variables Affecting Phosphorescence and Fluorescence
Work and Energy for Variable Forces

